SARS‐CoV‐2 evolves to reduce but not abolish neutralizing action
Yandi Zhang(Liaoning Normal University), Xionglin Fan(Huazhong University of Science and Technology), Jinge Cao(Huazhong University of Science and Technology), Mengze Gan(Chinese Center For Disease Control and Prevention), Leyong Yuan(Hubei University of Medicine), Feng Wang(Tongji Hospital), Xiaosong Lin(Huazhong University of Science and Technology), Hongyan Hou(Tongji Hospital), Jo‐Lewis Banga Ndzouboukou(Huazhong University of Science and Technology), Hui Fu(Huazhong University of Science and Technology), Zongjie Yao(Huazhong University of Science and Technology)
Cited by 14
Related Papers
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
Detection of IgM and IgG antibodies in patients with coronavirus disease 2019
|Clinical & Translational Immunology|2020|415
Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients
|Cell Reports|2021|184
CRISPR/Cas9-Based Mutagenesis of Starch Biosynthetic Genes in Sweet Potato (Ipomoea Batatas) for the Improvement of Starch Quality
|International Journal of Molecular Sciences|2019|147
Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections
|Allergy|2020|138